Fate Therapeutics, Inc. (FATE)
1.485
-0.08
(-4.81%)
USD |
NASDAQ |
Feb 27, 16:00
1.49
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Research and Development Expense (Quarterly) : 22.61M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| MannKind Corp. | 14.06M |
| Vertex Pharmaceuticals, Inc. | 973.70M |
| Ardelyx, Inc. | 21.94M |
| ACADIA Pharmaceuticals, Inc. | 84.76M |
| Alnylam Pharmaceuticals, Inc. | 372.22M |